Suzhou Innovent Biologics reported its Avastin biosimilar produced positive results in two China clinical trials. IBI305, a VEGF inhibitor, met its primary endpoints in two randomized clinical trials that compared the candidate to Roche’s Avastin: 1) a Phase III trial in 450 patients with advanced non-squamous non-small cell lung cancer (NSCLC) and 2) a pharmacokinetic study in 100 healthy volunteers. Innovent plans to release details from the two trials in future scientific journals and conferences.
Source: China Biotoday
